Crescendo Biologics (United Kingdom) a development-stage biopharma focused on a fragment antibody technology platforms, closed a $7.3M Series A financing. Participants include Sofinnova Partners, Aitua, Avlar BioVentures and Rainbow Seed Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.